Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs

House Oversight Committee report combats industry claims that lower drug prices would stifle innovation.


Fortify your mind! Join the Prospect today

Support The American Prospect's independent, nonprofit journalism by becoming a member today. You will stay engaged with the best and brightest political and public policy reporting and analyses, and help keep this website free from paywalls and open for all to read. Our membership levels offer a range of perks including an opt-in to receive the print magazine by mail.